G
Gian Luca De Salvo
Researcher at University of Southern California
Publications - 100
Citations - 3811
Gian Luca De Salvo is an academic researcher from University of Southern California. The author has contributed to research in topics: Rhabdomyosarcoma & Soft tissue sarcoma. The author has an hindex of 29, co-authored 92 publications receiving 2979 citations. Previous affiliations of Gian Luca De Salvo include University of Padua.
Papers
More filters
Journal ArticleDOI
A Randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the Sentinella/GIVOM trial.
G. Zavagno,Gian Luca De Salvo,Giuliano Scalco,Fernando Bozza,Luca Barutta,Paola Del Bianco,Marco Renier,C. Racano,Paolo Carraro,Donato Nitti +9 more
TL;DR: SLN biopsy is an effective and well-tolerated procedure, however, its safety should be confirmed by the results of larger randomized trials and meta-analyses.
Journal ArticleDOI
Bleomycin-Based Electrochemotherapy: Clinical Outcome from a Single Institution’s Experience with 52 Patients
Luca Giovanni Campana,Simone Mocellin,Michela Basso,Oliviero Puccetti,Gian Luca De Salvo,Vanna Chiarion-Sileni,Antonella Vecchiato,Luigi Corti,Carlo Riccardo Rossi,Donato Nitti +9 more
TL;DR: In a palliative setting, ECT proved to be safe, effective in all tumors treated, and useful in preserving patients’ quality of life.
Journal ArticleDOI
Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial
Giuseppe Lombardi,Gian Luca De Salvo,Alba A. Brandes,Marica Eoli,Roberta Rudà,Marina Faedi,Ivan Lolli,Andrea Pace,Bruno Daniele,Francesco Pasqualetti,Simona Rizzato,Luisa Bellu,Ardi Pambuku,Miriam Farina,Giovanna Magni,Stefano Indraccolo,Marina Paola Gardiman,Riccardo Soffietti,Vittorina Zagonel +18 more
TL;DR: Overall survival was significantly improved in the regorafenib group compared with the lomustine group, with a median overall survival of 7·4 months, and an encouraging overall survival benefit of regorAFenib in recurrent glioblastoma.
Journal ArticleDOI
Clinical Considerations on Sentinel Node Biopsy in Melanoma from an Italian Multicentric Study on 1,313 Patients (SOLISM–IMI)
Alessandro Testori,Gian Luca De Salvo,Maria Cristina Montesco,Giuseppe Trifirò,Simone Mocellin,Giorgio Landi,Giuseppe Macripò,Paolo Carcoforo,Giuseppe Ricotti,Giuseppe Giudice,Franco Picciotto,Davide Donner,Franco Di Filippo,Javier Soteldo,Dario Casara,Mauro Schiavon,Antonella Vecchiato,Sandro Pasquali,Federica Baldini,Giovanni Mazzarol,Carlo Riccardo Rossi +20 more
TL;DR: Regression in the primary melanoma seems to be a protective factor from metastasis in the SLN, and the SNB is important to more precisely assess the prognosis of patients with melanoma.
Journal ArticleDOI
Association Between MDM2–SNP309 and Age at Colorectal Cancer Diagnosis According to p53 Mutation Status
Chiara Menin,Maria Chiara Scaini,Gian Luca De Salvo,Martina Biscuola,Monica Quaggio,Giovanni Esposito,Claudio Belluco,Marco Montagna,Simona Agata,Emma D'Andrea,Donato Nitti,Alberto Amadori,Roberta Bertorelle +12 more
TL;DR: The data indicate that MDM2-SNP309 is a modifier of the age at colorectal cancer onset for patients whose tumors have a wild-type p53 gene.